No advantage of adjuvant sunitinib or sorafenib
Crossref DOI link: https://doi.org/10.1038/nrurol.2016.63
Published Online: 2016-03-31
Published Print: 2016-05
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Stone, Louise
Text and Data Mining valid from 2016-03-31
Article History
First Online: 31 March 2016